BMTCN Free Test(questions well answered)graded A+

BMTCN Free TestWhich of the following studies should be completed at regular intervals for a patient receiving long-term steroids? A. Positron emission tomography scan B. Magnetic resonance imaging C. Dual energy x-ray absorptiometry D. Computed tomography scan - correct answer C. Dual energy x-ray absorptiometry The major histocompatibility complex is responsible for: A. identification of self versus non-self. B. the release of histamine during a hemolytic transfusion reaction. C. the release of hematopoietic stem cells from the bone marrow. D. progenitor cell Golgi complex regulation. - correct answer A. identification of self versus non-self. What is the overall grade of acute graft-versus-host disease for a patient following transplant who has a maculopapular rash on the face and trunk, a direct bilirubin of 4 mg/dL, and approximately 1,200 mL/day of diarrhea? A. III B. IV C. I D. II - correct answer A. III Maculopapular rash 40.5% = grade 2 Bilirubin 4 mg/dL = grade 2 Diarrhea 1,200 mL/day = grade 2 What preventive measures can help reduce the occurrence of acute graft-versus-host disease? A. Using ABO-compatible donors B. Administering hematopoietic growth factor post-transplant C. Administering alemtuzumab and fludarabine D. Irradiating the stem cell product prior to infusion - correct answer C. Administering alemtuzumab and fludarabine Which of the following should be considered prior to administering a myeloablative conditioning regimen? A. Patient's gender B. Patient's disease C. Donor's age D. Donor's ethnicity - correct answer B. Patient's disease A patient is currently taking cyclosporine and has a new order for fluconazole. The nurse anticipates which of the following? A. Administering medications at separate times B. Suspecting blood medication levels will be inaccurate C. Increasing the dose of fluconazole D. Reducing the dose of cyclosporine - correct answer D. Reducing the dose of cyclosporine Which secondary malignancy is a patient most at risk for developing following an allogeneic HSCT? A. Colorectal cancer B. Chronic myeloid leukemia C. Ewing sarcoma